ZVRA
Zevra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.40
−1.12%Forward multiples
Based on analyst estimates
- P/E forward
- 14.52x
- P/E 2026E
- 11.31x
- P/E 2027E
- 13.40x
- P/E 2028E
- 8.89x
- P/S forward
- 4.53x
Trailing multiples
Trailing twelve months
- P/E TTM
- 12.91x
- PEG TTM
- —
- Price / book
- 3.38x
- Price / sales
- 5.41x
- Price / cash flow
- 22.05x
Enterprise value
- Enterprise value
- $516.3M
- EV / sales
- 3.79x
- EV / EBITDA
- 7.07x
- EV / EBIT
- 13.22x
- Market cap
- $736.4M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026